Nanox.AI, a subsidiary of Nano-X Imaging Ltd. (NASDAQ: NNOX), has taken two significant steps to advance its medical imaging analytics business. The company announced an exclusive three-year UK reseller agreement with Vertec Scientific for its HealthOST bone solution, and a separate optimization project with Intel to enable its imaging AI framework to run inference locally on hospital hardware rather than relying entirely on the cloud.
The UK agreement addresses a substantial unmet need: approximately 86,000 vertebral fragility fractures occur annually in the UK, with most remaining undiagnosed. HealthOST is designed to help identify these fractures by analyzing routine CT scans, which often capture additional anatomical information beyond the original clinical indication, including details related to the spine, coronary arteries, and liver. The deal includes minimum annual license commitments, providing a predictable revenue stream and a clear commercial pathway for Nanox.AI in the UK market.
The Intel collaboration focuses on optimizing Nanox.AI’s imaging AI framework to perform inference locally on hospital hardware. This could reduce dependence on cloud infrastructure, potentially lowering costs, improving data privacy, and enabling faster processing times. For hospitals, local inference may mean more seamless integration into existing workflows and greater scalability for AI-driven imaging analytics.
These developments matter because they highlight a dual strategy: expanding commercial reach through partnerships while enhancing the technical foundation to make AI more accessible and efficient for healthcare providers. As the demand for advanced medical imaging grows, solutions that can extract more value from existing scans without additional radiation or procedures could play a crucial role in early detection and preventive care.
For investors, the news signals progress in monetizing Nanox.AI’s technology. The latest updates relating to NNOX are available in the company’s newsroom at https://ibn.fm/NNOX. The announcement was distributed via InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio @ IBN. InvestorWire provides access to a vast network of wire solutions, including editorial syndication to 5,000+ outlets and social media distribution to millions of followers.
As healthcare systems seek to do more with existing resources, Nanox.AI’s efforts to commercialize its bone solution and optimize its AI for local deployment could position it as a key player in the growing market for imaging analytics. The success of these initiatives will depend on adoption by healthcare providers and the ability to demonstrate clinical and operational benefits. For now, the company is laying the groundwork to capture opportunities in both the UK and broader global markets.
